Work

Dissecting the predictive and therapeutic value of HLA-DR-expressing cytotoxic T lymphocytes in Breast Cancer

Year: 2025
Type: dissertation
Abstract: Breast cancer (BC) remains the most prevalent cancer in women worldwide, posing a significant public health challenge. Projections indicate an increase in BC incidence and mortality rates in the coming years, underscoring the urgent need for innovative and effective therapeutic strategies. The treatment landscape for BC is rapidly evolving, with neoadjuvant chemotherapy (NACT) continuing as a standard approach for managing high-risk or inoperable tumors. However, with a success rate below 50%, the effectiveness of NACT is limited, particularly in cases of chemotherapy-resistant tumors. While emerging therapies like immune checkpoint inhibitors show promise, especially in treating triple-negative breast cancer, their applicability across all BC subtypes remains limited. Consequently, novel approaches such as adoptive cellular therapy, which involves the ex vivo expansion of patient-derived T lymphocytes, are being investigated. Building on our previous research, which identified cytotoxic T lymphocytes (CTLs) with high HLA-DR expression within the BC tumor microenvironment as predictive of favorable responses to NACT, this study aims to further elucidate the role of HLA-DR expression in CTLs by investigating how HLA-DR expression enhances CTLs’ anti-tumor efficacy, offering potential advancements in T cell-based treatments. We hypothesize that increasing the frequency and functionality of HLA-DR-expressing CTLs can improve BC treatment outcomes, particularly in cases where conventional therapies are ineffective. This research addresses a critical unmet need by introducing a novel approach to enhance the effectiveness of T cell-based therapies. By optimizing HLA-DR expression in CTLs, we aim to deliver more personalized and effective immunotherapies for BC, especially for patients with resistant or difficult-to-treat tumors. To achieve this, we refined a protocol for the ex vivo expansion of HLA-DR-expressing CTLs and employed a 3D co-culture platform to assess the effects of various immune modulators on CTLs cytotoxicity against BC cells. Moreover, we investigated the role of metabolic modulation in enhancing CTLs function. Additionally, to deepen our understanding of HLA-DR regulation, we performed a bioinformatic analysis of single cell RNA sequencing (scRNA-seq) data from BC patients. xvi Our findings revealed that HLA-DR expression is crucial for CTLs to effectively target and eliminate tumor cells. Additionally, we found that blocking HLA-DR or depleting CD4+ T cells significantly impair CTLs activation and cytotoxicity, indicating that antigen presentation through HLA-DR and the involvement of CD4+ T cells are key mechanisms driving enhanced anti-tumor responses. Furthermore, our optimized ex vivo expansion protocol demonstrated that short-term stimulation, rather than long-term, significantly increases HLA-DR expression and consequently enhances CTLs functionality, emphasizing the importance of prioritizing cell quality over quantity for improved therapeutic efficacy. Additionally, we discovered that anti-PD-1 treatment of peripheral blood mononuclear cells further elevated HLA-DR levels in CTLs, thereby augmenting their anti-tumor potential. Notably, our in silico analysis also identified 34 co-expressed genes shared between PD 1 and HLA-DR in CTLs, including several non-coding RNAs, suggesting a potential PD-1- mediated regulatory pathway influencing HLA-DR expression. In conclusion, the present study underscores the importance of enhancing HLA-DR expression in CTLs as a promising strategy for improving T cell-based therapies for BC. We highlight the synergistic benefits of combining anti-PD-1 treatment with short-term stimulation, offering new avenues for more effective and personalized treatments for BC patients. These findings pave the way for future clinical applications aimed at improving outcomes in BC therapy.
Author: Salvador, Rute
Language: Portuguese
Subfield: Immunology
Open Access status: green
Award: G739892676
OpenAlex ID: W6981181196
Cites: 169
Cited by:
Related to: 7